⁸⁹Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs.

ABSTRACT:

Background

To better predict response to immune checkpoint therapy and toxicity in healthy tissues, insight in the in vivo behavior of immune checkpoint targeting monoclonal antibodies is essential. Therefore, we aimed to study in vivo pharmacokinetics and whole-body distribution of zirconium-89 (⁸⁹Zr) labeled programmed cell death protein-1 (PD-1) targeting pembrolizumab with positron-emission tomography (PET) in humanized mice.

Methods

Humanized (huNOG) and non-humanized NOG mice were xenografted with human A375M melanoma cells. PET imaging was performed on day 7 post ⁸⁹Zr-pembrolizumab (10 µg, 2.5 MBq) administration, followed by ex vivo biodistribution studies. Other huNOG mice bearing A375M tumors received a co-injection of excess (90 µg) unlabeled

SUBMITTER: van der Veen EL 

PROVIDER: S-EPMC7537332 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature